Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jin S. Ahn"'
Autor:
Rafael Rosell, Alice T. Shaw, Ali Zeaiter, Shirish M. Gadgeel, Emmanuel Mitry, Bogdana Balas, Jin S. Ahn, Maurice Perol, Johannes Noe, Sai-Hong Ignatius Ou, Peter N. Morcos, D. Ross Camidge, Solange Peters, Tony Mok, Dong Wan Kim, Rafal Dziadziuszko, Sophie Golding
Publikováno v:
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
The New England journal of medicine, vol. 377, no. 9, pp. 829-838
Universitat Autònoma de Barcelona
The New England journal of medicine, vol. 377, no. 9, pp. 829-838
Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18d35d488c552e94e96cbf18b7922921
https://doi.org/10.1056/nejmoa1704795
https://doi.org/10.1056/nejmoa1704795
Autor:
Eun Kyung Cho, Jin S. Ahn, Seock-Ah Im, Moon H. Lee, Dong Wan Kim, Yung-Jue Bang, Chul Won Jung, Noe Kyeong Kim, Jong T. Lee, Dae S. Heo
Publikováno v:
Cancer. 86:1109-1115
BACKGROUND SKI-2053R (SK Chemicals, Kyungki-Do, South Korea) is a new platinum derivative with antitumor activity against various cell lines, including cisplatin-resistant tumor cell lines. Preclinical studies have suggested that it is less nephrotox
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52fbbc43d781912c714236d67527f439
https://doi.org/10.1002/(sici)1097-0142(19991001)86:7<1109::aid-cncr3>3.0.co
https://doi.org/10.1002/(sici)1097-0142(19991001)86:7<1109::aid-cncr3>3.0.co
Autor:
Seung J.un Lee, Hey Y. Cho, Na-Young Ha, Soon Hee Kim, Jae W. Kim, Deok Gyeong Kang, Sung-Jo Kang, Young-Joon Lee, Jina Kim, Chang-Won Lee, Jong M. Bae, Woo S. Ha, Geun H. Ha, Soon Chan Hong, Jin S. Ahn
Publikováno v:
Electrophoresis. 23(24)
Hepatocellular carcinoma (HCC) is a common malignancy worldwide and is a leading cause of death. To contribute to the development and improvement of molecular markers for diagnostics and prognostics and of therapeutic targets for the disease, we have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63f6e7e405d744c175637a20bad33757
https://pubmed.ncbi.nlm.nih.gov/12481271
https://pubmed.ncbi.nlm.nih.gov/12481271
Autor:
Keun S Lee, Jung-Ae Lee, Hun H Song, Jaeho Byun, Jin S Ahn, Dae Y Zang, Young I Park, Se-Hyuck Park, Suk W Park, Eun-Sook Nam, Hyoun C Cho
Publikováno v:
American Journal of Clinical Oncology; Dec2004, Vol. 27 Issue 6, p638-639, 2p